Decheng Capital

Decheng Capital

Forbes Tech

Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein

DealStreetAsia

China regulators to penalise Luckin Coffee for accounting fraud

TechCrunch

Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH fundings through RADx program

$121,000,000 Venture capital (Series C)
FinSMEs , Pulse 2.0

Sema4 Closes $121M Series C Funding; Post-Money Valued at $1 Billion

TechCrunch

Using population health analysis to improve patient care brings Sema4 a $1.1 billion valuation

DealStreetAsia , Pulse 2.0

Luckin Coffee ousts chairman Lu, names Guo as CEO

DealStreetAsia

Luckin Coffee chairman ousted by shareholders: Reports

DealStreetAsia

Luckin Coffee co-founder Lu holds on to chairman role

DealStreetAsia

Luckin Coffee concludes internal probe ahead of vote on chairman removal

TechCrunch

After grinding investigation, Luckin Coffee confirms $300 million revenue fraud

TechCrunch

Luckin Coffee’s board is forcing out its chairman (also, chairman is forcing out the rest of the board)

TechCrunch

Luckin Coffee will unluckin’ly delist from Nasdaq following fraud allegations

$40,000,000 Venture capital
FinSMEs

Polares Medical Closes $40M Financing

TechCrunch

Luckin Coffee discloses that the Nasdaq really wants it gone

Xconomy

Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx

$100,000,000 Venture capital (Series C)
TechCrunch

Cue Health’s portable, fast COVID-19 test gains FDA emergency approval

$85,000,000 Venture capital (Series C)
FinSMEs , Pulse 2.0

Checkmate Pharmaceuticals Raises $85M in Series C Financing

Pulse 2.0

Gilead Sciences (GILD) Signs $2 Billion Deal With Arcus Biosciences (RCUS)

DealStreetAsia

China’s Starbucks rival Luckin Coffee shares crash on delisting risk

DealStreetAsia

Nasdaq notifies China’s Luckin Coffee of plans to delist it from US bourse